Viridian Therapeutics (VRDN) News Today $20.82 -0.72 (-3.34%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Viridian Therapeutics (NASDAQ:VRDN) Given New $47.00 Price Target at Royal Bank of CanadaDecember 18 at 3:23 AM | americanbankingnews.comTD Cowen Remains a Buy on Viridian Therapeutics (VRDN)December 18 at 2:50 AM | markets.businessinsider.comBreaking Down Viridian Therapeutics: 10 Analysts Share Their ViewsDecember 18 at 2:50 AM | benzinga.comViridian Therapeutics (VRDN) Gets a Buy from OppenheimerDecember 18 at 2:50 AM | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Viridian Therapeutics (NASDAQ:VRDN)December 18 at 1:35 AM | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 5.7% - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5.7% - Here's WhyDecember 17 at 3:09 PM | marketbeat.comViridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)December 17 at 1:01 PM | seekingalpha.comViridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Royal Bank of CanadaRoyal Bank of Canada lifted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday.December 17 at 10:35 AM | marketbeat.comViridian Therapeutics’ Veligrotug Outperforms in THRIVE-2 Trial, Boosting Buy RatingDecember 17 at 9:37 AM | markets.businessinsider.comLord Abbett & CO. LLC Purchases New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Lord Abbett & CO. LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 391,958 shares of the company's stock, valued at approximately $8,917,000. Lord AbbettDecember 17 at 5:11 AM | marketbeat.comWellington Management Group LLP Cuts Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Wellington Management Group LLP cut its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 16.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 235,987 shares of the company's stock after selling 48,057 shares during the period. WellingtDecember 17 at 3:43 AM | marketbeat.comViridian Therapeutics’ Veligrotug: Promising Phase 3 Results and Strong Buy RatingDecember 16 at 4:07 PM | markets.businessinsider.comViridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial DataDecember 16 at 4:07 PM | msn.comViridian stock soars 25% on Phase 3 data for veligrotugDecember 16 at 4:07 PM | msn.comViridian Therapeutics’ Veligrotug Shows Best-in-Class Potential in Phase 3 THRIVE-2 Trial for Chronic TEDDecember 16 at 4:07 PM | markets.businessinsider.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Up - Here's What HappenedViridian Therapeutics (NASDAQ:VRDN) Shares Gap Up - Here's What HappenedDecember 16 at 11:43 AM | marketbeat.comViridian Therapeutics' (VRDN) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday.December 16 at 10:59 AM | marketbeat.comViridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye DiseaseDecember 16 at 9:28 AM | investors.comViridian Therapeutics' eye disorder drug meets late-stage study goalDecember 16 at 7:10 AM | reuters.comViridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye DiseaseDecember 16 at 7:00 AM | businesswire.comY Intercept Hong Kong Ltd Takes $660,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Y Intercept Hong Kong Ltd acquired a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 29,002 shares of the company's stock, valued at approximately $660,000. OtherDecember 15 at 4:22 AM | marketbeat.comExome Asset Management LLC Buys New Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Exome Asset Management LLC acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 174,400 shares of the companyDecember 14, 2024 | marketbeat.comViridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024December 13, 2024 | businesswire.comBrokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $36.33December 13, 2024 | americanbankingnews.comPoint72 Asset Management L.P. Invests $788,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Point72 Asset Management L.P. purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 34,627 shares of the company's stock, valued at approximately $788,000. A numDecember 12, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Two Sigma Advisers LPTwo Sigma Advisers LP decreased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 15.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 444,800 shares of the company's stock after sellinDecember 10, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and nine have isDecember 10, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Lifted by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 6.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 516,213 shares of the company's stock after acquiring an additional 32,292 shaDecember 9, 2024 | marketbeat.comViridian Therapeutics' (VRDN) Outperform Rating Reiterated at Royal Bank of CanadaDecember 8, 2024 | americanbankingnews.comPolar Asset Management Partners Inc. Purchases 53,100 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Polar Asset Management Partners Inc. boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 48.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 163,000 shares of the company's stock after acquiring an additional 53,100 shaDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Invests $9.67 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Parkman Healthcare Partners LLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 425,000 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.comPDT Partners LLC Purchases New Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)PDT Partners LLC acquired a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,475 shares of the company's stoDecember 3, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Fmr LLCFmr LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 16.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,183,478 shares of the company's stock afDecember 2, 2024 | marketbeat.comWalleye Capital LLC Has $12.74 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Walleye Capital LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 30.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 560,007 shares of the company's stock after acquiringNovember 30, 2024 | marketbeat.comFisher Asset Management LLC Buys 99,427 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Fisher Asset Management LLC lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 25.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 494,924 shares of the company's stock after buying an additiNovember 28, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Boosted by Great Point Partners LLCGreat Point Partners LLC raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 50.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 750,000 shares of the company's stock after acNovember 27, 2024 | marketbeat.comAlgert Global LLC Has $2.61 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Algert Global LLC increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 107.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,913 shares of the company's stock after buying an adNovember 27, 2024 | marketbeat.comTD Cowen Initiates Coverage of Viridian Therapeutics (VRDN) with Buy RecommendationNovember 25, 2024 | msn.comViridian Therapeutics (NASDAQ:VRDN) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Monday.November 25, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Now Covered by Analysts at TD CowenTD Cowen assumed coverage on Viridian Therapeutics in a report on Monday. They set a "buy" rating on the stock.November 25, 2024 | marketbeat.comEagle Asset Management Inc. Decreases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Eagle Asset Management Inc. lessened its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 16.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 313,130 shares of the company'sNovember 25, 2024 | marketbeat.comPrincipal Financial Group Inc. Buys 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Principal Financial Group Inc. lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 1,603.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,810 shares of the company's stock after buying anNovember 22, 2024 | marketbeat.comB. Riley Has Bearish Forecast for VRDN FY2024 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - B. Riley dropped their FY2024 earnings per share (EPS) estimates for Viridian Therapeutics in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst K. Patel now expects that the company will earn ($4.November 20, 2024 | marketbeat.comViridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | msn.comEquities Analysts Issue Forecasts for VRDN FY2024 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at HC Wainwright raised their FY2024 EPS estimates for Viridian Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will posNovember 18, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 5.8% - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8% - Here's What HappenedNovember 15, 2024 | marketbeat.comFY2024 Earnings Estimate for VRDN Issued By Leerink PartnrsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for Viridian Therapeutics in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will postNovember 15, 2024 | marketbeat.comWhat is Lifesci Capital's Estimate for VRDN FY2024 Earnings?Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Research analysts at Lifesci Capital lowered their FY2024 EPS estimates for shares of Viridian Therapeutics in a report released on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earningsNovember 15, 2024 | marketbeat.comWedbush Has Pessimistic Outlook of VRDN FY2024 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Stock analysts at Wedbush lowered their FY2024 earnings estimates for Viridian Therapeutics in a research report issued on Tuesday, November 12th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($3.97) per shNovember 15, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by AnalystsShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and eight have assigned aNovember 15, 2024 | marketbeat.com Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼0.840.75▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼275▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HIMS News Today GH News Today OPCH News Today SHC News Today VCYT News Today BTSG News Today LFST News Today SGRY News Today CON News Today PRVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRDN Stock Alerts